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E-mail address: hgjeong@cnu.ac.kr (H.G. Jeong).The overexpression of metallothionein-2A (MT-2A) is frequently observed in invasive human breast
tumors and has been linked with more aggressive breast cancers. MT-2A overexpression led to the
induction of MDA-MB-231 breast cancer cell migratory and invasive abilities. The reduction of MT-
2A expression through small interfering RNA (siRNA) targeting MT-2A in invasive MDA-MB-231 cells
completely inhibited both cell invasion and migration. In addition, the expression of matrix
metalloproteinase-9 (MMP-9) and the transcriptional activity of AP-1 and NF-jB were upregulated
by MT-2A overexpression. Collectively, our results provide the ﬁrst demonstration that MT-2A pro-
motes breast cancer cell invasion by upregulating MMP-9 via AP-1 and NF-jB activation. Further-
more, we found that MT-2A silencing can inhibit breast cancer invasiveness.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction tumors were observed to have a higher expression of MT-2AmRNAThe rapid increase in the incidence rate of breast cancer has led
to the search for and identiﬁcation of biomarkers that can predict
risk for and future behavior of this malignancy and can aid in its
management. In this regard, several proteins, including estrogen
receptors bcl-2 and metallothionein (MT), have been identiﬁed as
potential biomarkers in breast cancer [1].
MTs are a group of low-molecular-weight (6–7 kDa) intracellu-
lar metal-binding proteins that are expressed in many tissues [2].
MT-1 and MT-2 are ubiquitously expressed, whereas MT-3 and
MT-4 are expressed predominantly in the central nervous system
and in the squamous epithelia, respectively [3]. MT plays an impor-
tant role in apoptosis and proliferation, which can inﬂuence the
carcinogenic process. MT-1 and MT-2 isoforms are expressed coor-
dinately in most organs, but the precise role of these MT isoforms
has not been well elucidated. The MT-2A mRNA transcript, which
has been reported to be the highest among all the functional
isoforms of MT detected in breast tissues, positively correlates with
cell proliferation and histological grade [4]. Histological grade 3chemical Societies. Published by E
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g, Yuseong-Gu, Daejeon 305-than grade 1 and 2 tumors. Recently, it has been demonstrated that
the downregulation of MT-2A arrests growth in the MCF-7 human
breast cancer cell lines, suggesting the close involvement of the
MT-2A isoform in the proliferative activity of breast cancer cells
[5,6]. Although the growth-promoting mechanism of MT-2A has
been well characterized, the mechanism by which MT-2A
enhances cell invasion and tumor metastasis is still unknown.
Metastasis is a complex, multi-step process that involves the
separation of cells from the primary tumor, intravasation, extrava-
sation, and the establishment of tumor cells at a secondary site [7].
The invasive ability of tumor cells is important in all of these steps.
Invasion requires the degradation of the basement membrane to
permit the egress and eventual ingress of malignant cells from
the primary tumor. Several invasion-related proteases, including
matrix metalloproteinase’s (MMPs), cysteine proteinases, and ser-
ine proteases, are responsible for this process [8–10]. In particular,
MMP-2 and MMP-9, the two predominately expressed MMPs in
cancer cells that are capable of degrading type IV collagen, are
thought to be directly involved in tumor cell growth and progres-
sion during metastasis [11,12]. Increased MMP activity is observed
in human breast, prostate, lung, and ovarian tumors [13,14].
Here we report that MT-2A induces MMP-9 upregulation,
invasion and migration of breast cancer cells. We further show that
the activation of both NF-kB and AP-1 signaling pathways are
required for the MT-2A-induced MMP-9 upregulation and for thelsevier B.V. All rights reserved.
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breast cancer cells.
2. Materials and methods
2.1. Establishment of MT-2A-overexpressing stable transfectants
MT-2A was ampliﬁed by RT-PCR using the primers 50-GAATT-
CATGGATCCCAACTGCT-30 and 50-GGATCCTCTGGCGCAGCAGCTG-
30. The MT-2A expression vector was constructed by inserting the
fragment of MT-2A into pMEX-HA (Dualsystems Biotech AG, Zur-
ich, Switzerland) and designated pMEX-MT-2A-HA. The human
breast cancer cell line MDA-MB231 (American Type Culture Collec-
tion, Manassas, VA) was grown in DMEM supplemented with
2 mM glutamine and 10% FBS (Gibco-BRL-Life Technologies (Grand
Island, NY), at 37 C in an atmosphere containing 5% CO2. The MT-
2A expression vector was transfected into MDA-MB231 cells and
subjected to antibiotic selection for 4 weeks. The stable transfec-
tants with the highest MT-2A expression were used for the
investigation.
2.2. Transient transfection and luciferase assays
The MMP-9 promoter, MMP-9 mAP-1, and MMP-9 mNF-kB con-
structs cloned into the pGL3-Basic luciferase vector (Promega)
were kind gifts from Dr. Wolfgang Eberhardt. MDA-MB231 cells
were transiently co-transfected with pCMV-b-gal and pGL3-
MMP-9-Luc or pGL3-MMP-9 mAP-1-Luc or pGL3-MMP-9 mNF-
kB-Luc, using the Lipofectamine 2000 reagent (Invitrogen, San Die-
go, CA, USA) according to the manufacturer’s protocol. Cells were
then lysed, and luciferase activity was measured using a lumino-
meter (Luminoscan Ascent; Thermo Electron Co.). Luciferase activ-
ity was normalized to b-galactosidase activity in cell lysates and
was expressed as an average of three independent experiments.
2.3. RNA preparation, semi-quantitative RT-PCT and real-time PCR
Total RNA was isolated from cells using an RNA isolation kit
(Takara Shuzo, Kyoto, Japan) according to the manufacturer’s pro-
tocol. The quality of the RNA was conﬁrmed by a ratio of >1.8 for
the optical densities at 260 and 280 nm. The PCR ampliﬁcation pro-
tocol was 30 cycles of 94 C for 30 s, 56 C for 30 s, and 72 C for
1 min. Ampliﬁed products were resolved by 1.5% agarose gel elec-
trophoresis. PCR product formation was continuously monitored
during the PCR using the Sequence Detection System software, ver-
sion 1.7 (Applied Biosystems, Foster City, CA, USA). Accumulated
PCR products were detected directly by monitoring the increase
in the reporter dye (SYBR) signal. The following primers were used
in this study: 50-TGACAGCGACAAGAAGTG-30 and 50-CAGTGAA-
GCGGTACATAGG-30 for MMP-9; 50-CAATTCCGACCTCGTCATCA-30
and 50-TCAGAGCCTTGGAGGAGCT-30 for TIMP1; 50-CCGGCTCCTGC-
AAATGCAAAGAGTG-30 and 50-CGCTCCCAGATGTAAAGAACGCGAC-30
for MT-2A; and 50-GATGATATCGCCGCGCTCGTCGTCGAC-30 and
50-AGCCAGGTCCAGACGCAGGATGGCATG-30 for b-actin. The quan-
tity of each transcript was calculated as described in the instru-
ment manual and normalized to the levels of b-actin.
2.4. Western blot analysis
Cells were washed with phosphate-buffered saline (PBS) and
were lysed on ice for 30 min in 100 ll of lysis buffer (120 mMNaCl,
40 mM Tris, pH 8, 0.1% Nonidet P-40). Lysates were centrifuged at
12 000 rpm for 30 min, and protein concentrations were deter-
mined using a BCA protein assay kit. Lysates (40 lg) were boiled
for 5 min and were electrophoresed in 10% SDS–polyacrylamide
gels. The separated proteins were transferred onto nitrocellulosemembranes and were probed with antibodies against HA-Tag
(detection of MT-2A-HA), MMP-9 (Cell Signaling Technology, Bev-
erly, MA) or b-actin (Santa Cruz, CA, USA), followed by anti-mouse
or anti-rabbit HRP conjugated secondary antibodies. The protein
bands were detected using an enhanced chemiluminescence Wes-
tern blotting detection kit.
2.5. Cell migration and invasion assay
Cell migrationwas assessedwith a Transwell insert system (Mil-
lipore Corp., Bedford, MA, USA) using polycarbonate membranes of
8 lmpore size. Invasion assays were performed using Transwell in-
serts precoated with Matrigel. MDA-MB231 cells were incubated in
DMEM with 10% FBS and were collected by trypsinization. Cells
(1  105 cells/mL) in serum-free medium were added to the inner
cup of a 48-well Transwell chamber that had been coated with
50 ll of Matrigel (1:10 dilution in serum-free medium; BD Biosci-
ences, Franklin Lakes,NJ,USA).Mediumsupplementedwith10%ser-
um or the indicated compounds were added to the outer cup. After
24 h, the cells that had migrated through the Matrigel and the 8-
lm pore-size membrane were ﬁxed, stained, and counted under a
light microscope. Each experiment was performed in triplicate.
2.6. Gelatin zymography
The enzymatic activities ofMMP-2 andMMP-9were determined
by gelatin zymography. Brieﬂy, cells were seeded to conﬂuence for
24 handweremaintained in serum-freemedium.Conditionedmed-
ia was collected 24 h after stimulation, mixed with non-reducing
sample buffer, and subjected to electrophoresis in 10% polyacryl-
amide gels containing 0.1% (w/v) gelatin. The gel was washed in
washing buffer containing 2.5% Triton X-100 and 50 mM Tris–HCl,
pH 7.5, and was incubated at 37 C for 24 h in 50 mM Tris–HCl, pH
7.5, 150 mM NaCl, 5 mM CaCl2, 1 mM ZnCl2, and 40 mmol/l NaN3.
The gel was stained with 0.25% (w/v) Coomassie brilliant blue in
45% (v/v) methanol and 1% (v/v) acetic acid. Gelatinolytic activity
was normalized against the protein content of the cultured cells.
2.7. RNA interference
Small interfering RNA (siRNA) was synthesized by Genolution
(Seoul, South Korea) with the following sequences: MT-2A, 50-
CCG GCT CCT GCA AAT GCA AAG AGT G-30. Cells, grown to 50% con-
ﬂuence were transfected using oligofectamine transfection reagent
(Invitrogen, Carlsbad, CA, USA) with MT-2A or scrambled siRNA
according to the manufacturer’s instructions.
2.8. Chromatin immunoprecipitation assay (CHIP assays)
Cells were cross-linked with formaldehyde, and the sonicated
chromatin–DNA complexes were precipitated with anti-p65 and
anti-c-Jun antibody. ChIP was carried out with Chromatin Immuno-
precipitation Assay Kit (Upstate Biotechnology Inc., Lake Placid, NY).
Then, the procedure followedmanufacturer’s protocol. PCR analysis
was carried out using 1 ll of puriﬁed DNA, and Platinum Taq DNA
polymerase (Invitrogen). After 40 ampliﬁcation cycles, PCR prod-
ucts were analyzed on 2% agarose gel with ethidium bromide.
2.9. Statistical analyses
All experiments were performed in triplicate. Differences be-
tween the two groups were evaluated using the Student’s t test.
A one-way analysis of variance (ANOVA) was used to determine
the signiﬁcance of differences between treatment groups. The
Newman-Keuls test was used for multi-group comparisons. Statis-
tical signiﬁcance was accepted for P-values < 0.01.
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3.1. Overexpression of MT-2A enhances migration and invasion of
MDA-MB231 cells
Cancer cell tissue invasion is important during metastasis. It has
previously been demonstrated that MDA-MB231 cells are able to
migrate through a Matrigel matrix [15]. As shown in Fig. 1A, we
transfected MDA-MB231 breast cancer cells with control (pMEX-
HA, Con) or MT-2A expression vectors (pMEX-MT-2A-HA) and se-
lected a stable cell line expressing a high level of the MT-2A. In vi-
tro transwell migration assays demonstrated that MT-2A enhanced
the migration of MDA-MB231 cells (Fig. 1B). In addition, the trans-
well invasion assay indicated that MT-2A-overexpressing cells
exhibited a higher invasive ability than MDA-MB231 cells alone
(Fig. 1C). Also, MT-2A overexpression led to the induction of
MCF-7 breast cancer cell migratory and invasive abilities (Supple-
mentary data). These data suggest that MT-2A enhances the meta-
static potential of cancer cells.
3.2. Upregulation of MMP-9 by MT-2A
MMP-9 is highly expressed in human cancers, and a direct rela-
tionship between cancer progression and gelatinase expressionA
B
C
GAPDH
MT2A
HA
Con
β-actin
Con MT2A
Con MT2A
Fig. 1. Increase of migration and invasion by MT-2A. MDA-MB-231 cells were transfected
expression of MT-2A was determined by western blot and semi-quantitative RT-PCR ana
migration assay (C). After 24 h, the cells on the bottom side of the ﬁlter were counted. M
the mean ± S.D. calculated from three independent experiments. ⁄Signiﬁcantly differentand activity has been established in many studies [18]. Real-time
PCR analysis was performed to determine the effects of MT-2A
on MMP-9 mRNA expression levels. As shown in Fig. 2A and B,
when the expression of MMP-9 in MT-2A-overexpressing cells
was investigated, we observed an increase in MMP-9 mRNA levels.
As the activity of MMP-9 is tightly regulated by the tissue inhibi-
tors of metalloproteinase’s (TIMPs) [16], we sought to investigate
the levels of TIMP mRNA following MT-2A overexpression; how-
ever, no differences were observed in MT-2A-overexpressing cells
(Fig. 2A). We further conﬁrmed the upregulation of MMP-9 as gel-
atin zymography assays demonstrated that the levels of active
MMP-9 increased in the culture medium of MT-2A-overexpressing
cells (Fig. 2C). In addition, immunoblotting conﬁrmed the upregu-
lation of MMP-9 in the conditioned medium (Fig. 2C). These data
suggest that MT-2A increases the expression and enzymatic activ-
ity of MMP-9 with no changes in TIMP-1 activity.
3.3. Silencing of MT-2A inhibits migration and invasion of MDA-
MB231 cells
As tumor invasion and metastasis are often associated with the
enhanced expression of MT-2A, we next sought to knock downMT-
2A in the MT-2A-overexpressing cells (Fig. 3A). We examined the
gene expression levels of MT-2A at 24 h post-transfection ofMT2A
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Fig. 2. MT-2A increases the expression and secretion of MMP-9. (A and B) Total
RNAs were isolated from control- and MT-2A-overexpressing cells and the
expression of MMP-9 and TIMP-1 were measured by semi-quantitative RT-PCR
and real-time PCR. Bars show the mean ± S.D. of three independent experiments,
performed in triplicate. ⁄P < 0.01, signiﬁcantly different from control. (C) Condi-
tioned media was collected and analyzed for the expression of and MMP-9 by
western blot analysis. Zymography assays were performed, and the gelatinolytic
activity of active MMP-9 (92 kDa) was visualized as clear bands against a blue
background of stained gelatin.
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in MT-2A expression (Fig. 3B). The MT-2A knockdown was con-
ﬁrmed; Western blot analysis revealed that the expression and
activity of MMP-9 in MDA-MB231 cells was effectively decreased
following MT-2A silencing (Fig. 3C). We further observed that the
reduction of MT-2A expression correlated with a signiﬁcant reduc-
tion in MDA-MB231 cell invasion and migration (Fig. 3D and E),
demonstrating that MT-2A plays a critical role in the induction of
these characteristics in MDA-MB231 cells.
3.4. AP-1 and NF-jB are crucial for the MT-2A-induced MMP-9
upregulation, invasion and migration of MDA-MB231 cells
The expression of MMP-9 is regulated at the transcriptional le-
vel through the binding of AP-1 and NF-jB at speciﬁc sequencesin the MMP-9 gene promoter [17,18]. To test whether these tran-
scription factors regulate MMP-9 expression in MT-2A-over-
expressing cells, cells were transiently transfected with a
reporter gene that included the wild-type MMP-9 promoter, a
promoter with mutations in the NF-jB site, or a promoter with
mutations in AP-1 sites. As shown in Fig. 4A, MT-2A-overexpress-
ing cells increased wild-type MMP-9 promoter activity compared
to the control cells. However, the transcriptional activity of the
MMP-9 AP-1 and NF-jB mutant reporters were unaffected in
MT-2A-overexpressing cells, suggesting that the target of MT-2A
was the AP-1 and NF-jB transcription factors (Fig. 4A). To conﬁrm
these ﬁndings, cells were transiently transfected with reporter
vectors that included tandem repeats of the AP-1 and NF-jB bind-
ing sites. We observed that MT-2A-overexpressing cells increased
the levels NF-jB and AP-1 transcriptional activity, conﬁrming MT-
2A activation of these signaling pathways (Fig. 4B). We subse-
quently performed ChIP assays using antibodies against NF-jB
and AP-1, which further conﬁrmed the direct binding of endoge-
nous NF-jB and AP-1 to the MMP-9 promoter (Fig. 4C). To address
the functional roles of NF-jB and AP-1 in MMP-9 expression and
invasion/migration of MT-2A-overexpressing cells, we used the
pharmacological inhibitors curcumin (a speciﬁc inhibitor of AP-1
activation), and Bay11-7802 (an inhibitor of NF-jB). Fig. 4D dem-
onstrates that treatment with 10 lM curcumin or Bay11-7802 sig-
niﬁcantly inhibited MT-2A-induced MMP-9 expression as
observed by gelatin zymogram assays. Moreover, the invasion
and migration of MT-2A-overexpressing cells was signiﬁcantly
inhibited by 10 lM of curcumin or Bay11-7802 (Fig. 4E). These
data demonstrate that the MT-2A-induced MMP-9 upregulation,
and subsequent invasive and migratory ability of MDA-MB231
cells, requires the activation of NF-jB and AP-1 signaling
pathways.4. Discussion
Because metastasis is the principal cause of death from breast
cancer, strategies for the development of therapeutic interventions
to regulate breast cancer metastasis are of great importance. MTs
have been implicated in breast cancer progression as oncogenic
proteins, promoting cell invasion in several types of cancers [19].
Although the downregulation of MT-2A by siRNA in breast cancer
cells results in the induction of growth arrest and apoptosis, the
exact mechanism by which MT-2A affects cancer cell invasion in
breast cancer has not been well elucidated [6]. In the current study,
we attempted to elucidate the mechanisms of MT-2A mediated
induction of breast cancer invasion. In MT knockout mice, impaired
angiogenesis and wound healing have been reported in a model of
cortical freeze injury [20]. The MT-2A data suggests a possible rela-
tionship between the invasiveness of breast cancer cells and the
expression of MT-2A. Furthermore, there is evidence that MT-2A
regulates the genes involved in angiogenesis and metastasis. Using
siRNA mediated knock-down of MT-2A, the present study reveals
MT-2A as an important target in the invasion and migration of
MDA-MB-231 cells consistent with the reported major regulatory
role of MT in cancer metastasis.
The originally described tumor-associated role of MMP-9 is in
the degradation of the basement membrane. Indeed, the enhanced
invasive activity of cancer cells is observed when MMP-9 is ectop-
ically expressed. Pathological investigations also demonstrate that
the expression of MMP-9 is strongly associated with tumor metas-
tasis and is frequently negatively correlated with patient’s survival.
Clinical studies have demonstrated a correlation between MT-2A
expression and MMP-9 in breast cancer [20]. It is possible that
the poor prognosis of breast cancer is associated with MT-2A over-
expression and may be mediated by MMP-9. In the present study,
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Fig. 3. Inhibition of MMP-9 expression and cell invasion by MT-2A siRNA. MDA-MB-231 cells or MT-2A-overexpressing cells were transfected with control (Con) or MT-2A
siRNA vectors for 24 h. (A) Cellular proteins were also extracted for the determination of MT-2A protein levels by western blot analysis in MT-2A-overexpressing cells. (B)
Total RNA was harvested for the study of MMP-9 expression by real-time PCR in MDA-MB-231 cells. (C) Conditioned media was collected, and MMP-9 activity in MDA-MB-
231 cells was determined by gelatin zymography and by western blot analysis. (D and E) Cells transfected with siRNA for MT-2A were subjected to transwell migration assay
(D) or in vitro invasion assays (E) in MDA-MB-231 cells. After 24 h, the cells on the bottom side of the ﬁlter were counted. Migrating cells were imaged under a phase-contrast
microscope. Each bar represents the mean ± S.D. calculated from three independent experiments. ⁄Signiﬁcantly different from control (P < 0.01).
H.G. Kim et al. / FEBS Letters 585 (2011) 421–428 425we demonstrate that overexpression of MT-2A increases MMP-9
expression to promote migration and invasion of breast cancer
cells. We sought to further investigate if direct gene transcription
is a potential mechanism for the MT-2A-induced MMP-9 upregula-
tion of MDA-MB231 through luciferase reporter assays. The pro-
moter region of MMP-9 has binding sites for AP-1 and NF-jB,and the important roles of AP-1 and NF-jB have been reported
in MMP-9 gene activation [21,22]. In the present study, mutational
analyses of the promoter region revealed that the major target of
MT-2A was AP-1 and NF jB, a ﬁnding that was further conﬁrmed
through the use of reporter plasmids containing synthetic ele-
ments speciﬁc for various transcription factors. In addition, a direct
A
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were ampliﬁed by PCR. (D) MT-2A-overexpressing cells were treated with 10 lM of curcumin or Bay11-7802 for 24 h. Conditioned media was collected, and the gelatinolytic
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panel) for 24 h. Each bar represents the mean ± S.D. calculated from three independent experiments. ⁄Signiﬁcantly different from control (P < 0.01). ⁄⁄Signiﬁcantly different
from MT-2A-overexpressing control (P < 0.01).
426 H.G. Kim et al. / FEBS Letters 585 (2011) 421–428association between AP-1/NF-jB and the MMP-9 promoter by
chromatin immunoprecipitation was observed. We further con-
ﬁrmed this ﬁnding by demonstrating that MT-2A-induced invasion
and migration were signiﬁcantly inhibited in the presence of cur-
cumin or Bay11-7802, speciﬁc inhibitors of the AP-1 or NF-jB
pathways, respectively.
Taken together, our results provide the ﬁrst evidence that the
upregulation of MMP-9 is one of the mechanisms by which MT-2A promotes cell invasion. Our results also raise the possibility that
the inhibition of MT-2A may suppress tumor invasion. We also
provide evidence for the importance of the AP-1 and NF-jB path-
ways in MMP-9 upregulation and invasion of MDA-MB231 cells
by MT-2A. Given that MT-2A is one of the most important proteins
in human breast cancer and thus is an attractive therapeutic target,
our ﬁndings may provide a molecular basis for the promoting role
of MT-2A in breast cancer progression.
CMMP-9
INPUT
IgG p65 (IP)
MT2A+ +-
MMP-9
INPUT
IgG c-Jun (IP)
MT2A+ +-
D MMP-9
- - -
-+-
+--
MT2A + + +
curcumin 10 µM
Bay11-780 10 µM
- + -
- - +
E
- - -
-+-
+--
MT2A + + +
curcumin 10 µM
Bay11-780 10 µM
- + -
- - +
0
50
100
150
200
250
****
*
M
ig
ra
te
d 
ce
lls
 (%
 o
f c
on
tro
l)
0
50
100
150
200
250
In
va
de
d 
ce
lls
 (%
 o
f c
on
tro
l)
****
*
- - -
-+-
+--
MT2A + + +
curcumin 10 µM
Bay11-780 10 µM
- + -
- - +
Fig. 4 (continued)
H.G. Kim et al. / FEBS Letters 585 (2011) 421–428 427Conﬂict of interest statement
The authors declare no conﬂict of interest.
Acknowledgments
This study was supported by grants from the Korea Research
Foundation Grant funded by the Korean Government (KRF-2008-
313-E00741).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.12.030.
References
[1] Bay, B.H., Jin, R., Huang, J. and Tan, P.H. (2006) Metallothionein as a prognostic
biomarker in breast cancer. Exp. Biol. Med. 231, 1516–1521.
[2] Vasak, M. (2005) Advances in metallothionein structure and functions. J. Trace
Elem. Med. Biol. 19, 13–17.
[3] Inoue, K., Takano, H., Shimada, A. and Satoh, M. (2009) Metallothionein as an
anti-inﬂammatory mediator. Mediators Inﬂamm. 2009, 101659.
[4] Cherian, M.G., Jayasurya, A. and Bay, B.H. (2003) Metallothioneins in human
tumors and potential roles in carcinogenesis. Mutat. Res. 533, 201–209.
[5] Jin, R., Chow, V.T., Tan, P.H., Dheen, S.T., Duan, W. and Bay, B.H. (2002)
Metallothionein 2A expression is associated with cell proliferation in breast
cancer. Carcinogenesis 23, 81–86.
[6] Lim, D., Jocelyn, K.M., Yip, G.W. and Bay, B.H. (2009) Silencing the
Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase
involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett. 276,
109–117.
[7] Geiger, T.R. and Peeper, D.S. (2009) Metastasis mechanisms. Biochim. Biophys.
Acta 1796, 293–308.[8] Sreenath, T., Matrisian, L.M., Stetler-Stevenson, W., Gattoni-Celli, S. and
Pozzatti, R.O. (1992) Expression of matrix metalloproteinase genes in
transformed rat cell lines of high and low metastatic potential. Cancer Res.
52, 4942–4947.
[9] Denhardt, D.T., Greenberg, A.H., Egan, S.E., Hamilton, R.T. and Wright, J.A.
(1987) Cysteine proteinase cathepsin L expression correlates closely with the
metastatic potential of H-ras-transformed murine ﬁbroblasts. Oncogene 2,
55–59.
[10] Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L.G., Brodt, P., Goltzman, D.
and Rabbani, S.A. (1994) Urokinase overproduction results in increased
skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54, 2372–
2377.
[11] Sluijter, J.P., de Kleijn, D.P. and Pasterkamp, G. (2006) Vascular remodeling and
protease inhibition–bench to bedside. Cardiovasc. Res. 69, 595–603.
[12] Deryugina, E.I. and Quigley, J.P. (2006) Matrix metalloproteinases and tumor
metastasis. Cancer Metastasis Rev. 25, 9–34.
[13] Kohrmann, A., Kammerer, U., Kapp, M., Dietl, J. and Anacker, J. (2009)
Expression of matrix metalloproteinases (MMPs) in primary human breast
cancer and breast cancer cell lines: new ﬁndings and review of the literature.
BMC Cancer 9, 188.
[14] Roy, R., Yang, J. and Moses, M.A. (2009) Matrix metalloproteinases as novel
biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol.
27, 5287–5297.
[15] Walter-Yohrling, J., Cao, X., Callahan, M., Weber, W., Morgenbesser, S.,
Madden, S.L., Wang, C. and Teicher, B.A. (2003) Identiﬁcation of genes
expressed in malignant cells that promote invasion. Cancer Res. 63, 8939–
8947.
[16] Kazes, I., Elalamy, I., Sraer, J.D., Hatmi, M. and Nguyen, G. (2000) Platelet
release of trimolecular complex components MT1-MMP/TIMP2/MMP2:
involvement in MMP2 activation and platelet aggregation. Blood 96, 3064–
3069.
[17] Eberhardt, W., Schulze, M., Engels, C., Klasmeier, E. and Pfeilschifter, J. (2002)
Glucocorticoid-mediated suppression of cytokine-induced matrix
metalloproteinase-9 expression in rat mesangial cells: involvement of
nuclear factor-kappaB and Ets transcription factors. Mol. Endocrinol. 16,
1752–1766.
[18] Cho, H.J., Kang, J.H., Kwak, J.Y., Lee, T.S., Lee, I.S., Park, N.G., Nakajima, H.,
Magae, J. and Chang, Y.C. (2007) Ascofuranone suppresses PMA-mediated
matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK-
and Ap1-dependent mechanisms. Carcinogenesis 28, 1104–1110.
428 H.G. Kim et al. / FEBS Letters 585 (2011) 421–428[19] Yap, X., Tan, H.Y., Huang, J., Lai, Y., Yip, G.W., Tan, P.H. and Bay, B.H. (2009)
Over-expression of metallothionein predicts chemoresistance in breast
cancer. J. Pathol. 217, 563–570.
[20] Zbinden, S., Wang, J., Adenika, R., Schmidt, M., Tilan, J.U., Najaﬁ, A.H., Peng, X.,
Lassance-Soares, R.M., Iantorno, M., Morsli, H., Gercenshtein, L., Jang, G.J.,
Epstein, S.E. and Burnett, M.S. (2010) Metallothionein enhances angiogenesis
and arteriogenesis by modulating smooth muscle cell and macrophage
function. Arterioscler. Thromb. Vasc. Biol. 30, 477–4782.[21] Hwang, Y.P., Yun, H.J., Kim, H.G., Han, E.H., Lee, G.W. and Jeong, H.G. (2010)
Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via
inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent
mechanisms. Biochem. Pharmacol. 79, 1714–1726.
[22] Pan, M.H., Chiou, Y.S., Chen, W.J., Wang, J.M., Badmaev, V. and Ho, C.T. (2009)
Pterostilbene inhibited tumor invasion via suppressing multiple signal
transduction pathways in human hepatocellular carcinoma cells.
Carcinogenesis 30, 1234–1242.
